Endothelin receptor antagonist

Takuya Kishi, Kenji Sunagawa

    研究成果: Contribution to journalReview article査読

    1 被引用数 (Scopus)

    抄録

    Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased. Restoration of this imbalance by targeted therapies such as endothelin receptor antagonists should further improve treatment options for the management of PAH. Current treatment algorithms for PAH recommend bosentan as first-line treatment for PAH in functional class III. Recent many trials suggested that endothelin receptor antagonist, bosentan, caused good results in idiopathic PAH and PAH associated with chronic thromboembolism, collagen diseases, and congenital heart diseases.

    本文言語英語
    ページ(範囲)2152-2156
    ページ数5
    ジャーナルNippon rinsho. Japanese journal of clinical medicine
    66
    11
    出版ステータス出版済み - 11 2008

    All Science Journal Classification (ASJC) codes

    • 医学(全般)

    フィンガープリント

    「Endothelin receptor antagonist」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル